Pfizer to acquire Reviral as RSV race continues

The proposed USD 525m acquisition includes therapeutic candidates within the RSV indication, which Bavarian Nordic is also targeting.


Pharmaceutical giant Pfizer is continuing to expand its efforts within the RSV indication, fresh off success with its Covid-19 vaccine.

Now, this has led the firm to enter into an acquisition agreement with biopharmaceutical firm Reviral, which develops antiviral treatments for respiratory syncytial virus (RSV).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs